A group of researchers at the University of Tennessee Graduate School of Medicine in Knoxville has created technology that provides non-invasive detection of amyloidosis, a disease known to occur in Type 2 diabetes, myeloma, rheumatoid arthritis, Alzheimer’s and other fatal or debilitating diseases. Currently there is no detection for amyloidosis available in the U.S., and the median survival rate is four years.
The technology uses Positron Emission Tomography/Computed Tomography (PET/CT) imaging to provide whole-body visualization of amyloidosis.
The imaging technology led to the creation of Solex LLC, a new UT startup company. The University of Tennessee Research Foundation recently entered into a license agreement with Solex, to help commercialize the technology.
Solex developers from the UT Graduate School of Medicine include Jonathan Wall, Ph.D., Stephen Kennel, Ph.D., Emily Martin, B.S., Tina Richey, M.S., and Alan Stuckey, B.A., CNMT.